Design, molecular modelling and synthesis of novel benzothiazole derivatives as BCL-2 inhibitors.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 09 2023
20 09 2023
Historique:
received:
09
03
2023
accepted:
31
08
2023
medline:
22
9
2023
pubmed:
21
9
2023
entrez:
20
9
2023
Statut:
epublish
Résumé
Apoptosis plays a crucial role in cancer pathogenesis and drug resistance. BCL-2 family of enzymes is considered as one of the key enzymes which is involved in apoptosis. When there is disruption in the balance between anti-apoptotic and pro-apoptotic members of the BCL-2 family apoptosis is dysregulated in the affected cells. Herein, 33 novel benzothiazole-based molecules 7a-i, 8a-f, 9a-b, 12a-e, 13a-d, 14a,b, and 17a-j were designed, synthesized and tested for their BCL-2 inhibitory activity. Scaffold hopping strategy was applied in designing of the target compounds. Compounds 13c and 13d showed the highest activity with IC
Identifiants
pubmed: 37730790
doi: 10.1038/s41598-023-41783-1
pii: 10.1038/s41598-023-41783-1
pmc: PMC10511702
doi:
Substances chimiques
Benzothiazoles
0
Antineoplastic Agents
0
Proto-Oncogene Proteins c-bcl-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15554Informations de copyright
© 2023. Springer Nature Limited.
Références
Avendaño, C. & Menéndez, J. C. Medicinal Chemistry of Anticancer Drugs 2nd edn, 1–740 (Elsevier, 2015).
doi: 10.1016/B978-0-444-62649-3.00001-6
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144(5), 646–674 (2011).
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Renehan, A. G., Booth, C. & Potten, C. S. What is apoptosis, and why is it important?. BMJ 322(7301), 1536–1538 (2001).
doi: 10.1136/bmj.322.7301.1536
pubmed: 11420279
pmcid: 1120576
Soliman, A. M. et al. Induction of apoptosis, cytotoxicity and radiosensitization by novel 3,4-dihydroquinazolinone derivatives. Bioorg. Med. Chem. Lett. 49, 128308 (2021).
doi: 10.1016/j.bmcl.2021.128308
pubmed: 34363937
Wong, R. S. Y. Apoptosis in cancer: From pathogenesis to treatment. J. Exp. Clin. Cancer Res. 30(1), 87 (2011).
doi: 10.1186/1756-9966-30-87
pubmed: 21943236
pmcid: 3197541
Kasibhatla, S. & Tseng, B. Why target apoptosis in cancer treatment?. Mol. Cancer Ther. 2(6), 573–580 (2003).
pubmed: 12813137
Boice, A. & Bouchier-Hayes, L. Targeting apoptotic caspases in cancer. Biochim. Biophys. Acta Mol. Cell Res. 1867(6), 118688 (2020).
doi: 10.1016/j.bbamcr.2020.118688
pubmed: 32087180
pmcid: 7155770
Van Opdenbosch, N. & Lamkanfi, M. Caspases in cell death, inflammation, and disease. Immunity 50(6), 1352–1364 (2019).
doi: 10.1016/j.immuni.2019.05.020
pubmed: 31216460
pmcid: 6611727
Garrido, C. et al. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 13(9), 1423–1433 (2006).
doi: 10.1038/sj.cdd.4401950
pubmed: 16676004
Pfeffer, C. M. & Singh, A. T. K. Apoptosis: A target for anticancer therapy. Int. J. Mol. Sci. 19, E448. https://doi.org/10.3390/ijms19020448 (2018).
doi: 10.3390/ijms19020448
Reed, J. C. & Pellecchia, M. Apoptosis-based therapies for hematologic malignancies. Blood 106(2), 408–418 (2005).
doi: 10.1182/blood-2004-07-2761
pubmed: 15797997
Adams, J. M. & Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26(9), 1324–1337 (2007).
doi: 10.1038/sj.onc.1210220
pubmed: 17322918
pmcid: 2930981
Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: Changing partners in the dance towards death. Cell Death Differ. 25(1), 65–80 (2018).
doi: 10.1038/cdd.2017.186
pubmed: 29149100
Warren, C. F. A., Wong-Brown, M. W. & Bowden, N. A. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 10(3), 177 (2019).
doi: 10.1038/s41419-019-1407-6
pubmed: 30792387
pmcid: 6384907
Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87(1), 99–163 (2007).
doi: 10.1152/physrev.00013.2006
pubmed: 17237344
Hata, A. N., Engelman, J. A. & Faber, A. C. The BCL2 family: Key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 5(5), 475–487 (2015).
doi: 10.1158/2159-8290.CD-15-0011
pubmed: 25895919
pmcid: 4727530
Kvansakul, M. & Hinds, M. G. The Bcl-2 family: Structures, interactions and targets for drug discovery. Apoptosis 20(2), 136–150 (2015).
doi: 10.1007/s10495-014-1051-7
pubmed: 25398535
Chan, S. L. & Yu, V. C. Proteins of the bcl-2 family in apoptosis signalling: From mechanistic insights to therapeutic opportunities. Clin. Exp. Pharmacol. Physiol. 31(3), 119–128 (2004).
doi: 10.1111/j.1440-1681.2004.03975.x
pubmed: 15008953
Youle, R. J. & Strasser, A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9(1), 47–59 (2008).
doi: 10.1038/nrm2308
pubmed: 18097445
Obeng, E. Apoptosis (programmed cell death) and its signals—A review. Braz J Biol 81(4), 1133–1143 (2021).
doi: 10.1590/1519-6984.228437
pubmed: 33111928
Shimizu, S. et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 6(12), 1221–1228 (2004).
doi: 10.1038/ncb1192
pubmed: 15558033
Reed, J. S. et al. The role of MHC class I allele Mamu-A*07 during SIV(mac)239 infection. Immunogenetics 63(12), 789–807 (2011).
doi: 10.1007/s00251-011-0541-9
pubmed: 21732180
pmcid: 3706270
Khan, K. H., Blanco-Codesido, M. & Molife, L. R. Cancer therapeutics: Targeting the apoptotic pathway. Crit. Rev. Oncol. Hematol. 90(3), 200–219 (2014).
doi: 10.1016/j.critrevonc.2013.12.012
pubmed: 24507955
Kapoor, I. et al. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 11(11), 941 (2020).
doi: 10.1038/s41419-020-03144-y
pubmed: 33139702
pmcid: 7608616
Ishikawa, M. & Hashimoto, Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J. Med. Chem. 54(6), 1539–1554 (2011).
doi: 10.1021/jm101356p
pubmed: 21344906
Sleebs, B. E. et al. Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity. J. Med. Chem. 54(6), 1914–1926 (2011).
doi: 10.1021/jm101596e
pubmed: 21366295
Perez, H. L. et al. Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists. Bioorg. Med. Chem. Lett. 22(12), 3946–3950 (2012).
doi: 10.1016/j.bmcl.2012.04.103
pubmed: 22608961
Schroeder, G. M. et al. Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists. Bioorg. Med. Chem. Lett. 22(12), 3951–3956 (2012).
doi: 10.1016/j.bmcl.2012.04.106
pubmed: 22608393
Touré, B. B. et al. The role of the acidity of N-heteroaryl sulfonamides as inhibitors of bcl-2 family protein-protein interactions. ACS Med. Chem. Lett. 4(2), 186–190 (2013).
doi: 10.1021/ml300321d
pubmed: 24900652
pmcid: 4027142
Filippakopoulos, P. et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149(1), 214–231 (2012).
doi: 10.1016/j.cell.2012.02.013
pubmed: 22464331
pmcid: 3326523
Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28(1), 235–242 (2000).
doi: 10.1093/nar/28.1.235
pubmed: 10592235
pmcid: 102472
Pettersen, E. F. et al. UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 25(13), 1605–1612 (2004).
doi: 10.1002/jcc.20084
pubmed: 15264254
Gibson, C. L. et al. Diversity oriented syntheses of fused pyrimidines designed as potential antifolates. Org. Biomol. Chem. 7(9), 1829–1842 (2009).
doi: 10.1039/b818339b
pubmed: 19590778
Leow, M. L. et al. Benzofuran-based estrogen receptor α modulators as anti-cancer therapeutics: In silico and experimental studies. Curr. Med. Chem. 20(22), 2820–2837 (2013).
doi: 10.2174/0929867311320220007
pubmed: 23531218
González-Alvarez, M. et al. Development of novel copper(II) complexes of benzothiazole- N-sulfonamides as protective agents against superoxide anion. Crystal structures of [Cu( N-2-(4-methylbenzothiazole)benzenesulfonamidate)(2)(py)(2)] and [Cu( N-2-(6-nitrobenzothiazole)naphthalenesulfonamidate)(2)(py)(2)]. J. Biol. Inorg. Chem. 8(12), 112–20 (2003).
doi: 10.1007/s00775-002-0394-7
pubmed: 12459905
Manoharan, D. et al. Synthesis, characterization and evaluation of antidiabetic activity of novel indoline derivatives. Bangladesh J. Pharmacol. 12, 20 (2017).
doi: 10.3329/bjp.v12i2.30872
Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6(10), 813–823 (2006).
doi: 10.1038/nrc1951
pubmed: 16990858
Wu, G. et al. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J. Comput. Chem. 24(13), 1549–1562 (2003).
doi: 10.1002/jcc.10306
pubmed: 12925999